title: Recent advances in management of diabetic macular edema.
abstract: Diabetic macular edema (DME) is the leading cause of moderate vision loss in diabetics. Modalities to image and monitor DME have evolved much in the last decade. Systemic control is the most important part of management. Available ocular management options include intravitreal antivascular endothelial growth factor (anti-VEGF) agents, laser, steroids (intravitreal or peribulbar), vitrectomy, topical medications and others. Anti-VEGF agents are increasingly being used in clinical practice with good clinical response and are currently the preferred mode of treatment worldwide.
authors: C/o-Prof. Yog Raj Sharma, Chief, Room 488, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences (AIIMS), New Delhi, India- 110029. koushiktripathy@gmail.com.
authors: Koushik
authors: K
authors: Tripathy
authors: Yog Raj
authors: YR
authors: Sharma
authors: Karthikeya
authors: K
authors: R
authors: Rohan
authors: R
authors: Chawla
authors: Varun
authors: V
authors: Gogia
authors: Subodh Kumar
authors: SK
authors: Singh
authors: Pradeep
authors: P
authors: Venkatesh
authors: Rajpal
authors: R
authors: Vohra
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D003920:Diabetes Mellitus / Q000453:epidemiology; D003930:Diabetic Retinopathy / Q000175:diagnosis* / Q000628:therapy*; D019468:Disease Management; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D053685:Laser Therapy; D008269:Macular Edema / Q000175:diagnosis* / Q000503:physiopathology* / Q000628:therapy*; D013256:Steroids / Q000494:pharmacology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014821:Vitrectomy
chemical_list: D020533:Angiogenesis Inhibitors; D013256:Steroids; D042461:Vascular Endothelial Growth Factor A